# VWA5A Antibody

Catalog No: #36278

Orders: order@signalwayantibody.com
Support: tech@signalwayantibody.com

## Description

| | |
|---|---|
| Product Name | VWA5A Antibody |
| Host Species | Rabbit |
| Clonality | Polyclonal |
| Purification | Antigen affinity purification. |
| Applications | WB IHC |
| Species Reactivity | Hu |
| Specificity | The antibody detects endogenous levels of total VWA5A protein. |
| Immunogen Type | Recombinant Protein |
| Immunogen Description | Fusion protein corresponding to residues near the C terminal of human von Willebrand factor A domain containing 5A |
| Target Name | VWA5A |
| Other Names | BCSC1; BCSC-1; LOH11CR2A |
| Accession No. | Swiss-Prot#: O00534NCBI Gene ID: 4013Gene Accssion: BC001234 |
| Uniprot | O00534 |
| GeneID | 4013; |
| SDS-PAGE MW | 86kd |
| Concentration | 2.2mg/ml |
| Formulation | Rabbit IgG in pH7.4 PBS, 0.05% NaN3, 40% Glycerol. |
| Storage | Store at -20°C |

## Application Details

Western blotting: 1:500-1:2000

Immunohistochemistry: 1:100-1:300

## Images




Gel: 6%SDS-PAGE
Lysates (from left to right): Adrenal pheochromocytoma tissue,Jurkat and A549 cell
Amount of lysate: 40ug per lane
Primary antibody: 1/275 dilution
Secondary antibody dilution: 1/8000
Exposure time: 10 seconds



Immunohistochemical analysis of paraffin-embedded Human lung cancer tissue using #36278 at dilution 1/60.

## Background

VWA5A (von Willebrand factor A domain containing 5A), also known as BCSC-1 (breast cancer suppressor candidate 1) or LOH11CR2A (loss of heterozygosity 11 chromosomal region 2 gene A protein), is a 786 amino acid protein containing one VIT domain and one VWFA domain. VWA5A is expressed at low levels in various tissues, with no expression found in 80% of tumor cell lines. Likely acting as a tumor suppressor gene, deletion of VWA5A leads to loss of heterozygosity (LOH) in breast and ovarian tumors, and may have an important role as a potential gene therapy target. Abnormal expression of VWA5A may lead to an increase in adhesion of CNE-2L2 cells associated with an increase in expression of E-cadherin, alpha-catenin, and p53, resulting in a decrease of malignant activity in cells with ectopic expression of VWA5A.

Note: This product is for in vitro research use only